Bortezomib

Generic Name: Bortezomib

Brand Names: Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₅BN_₄O_₄

CAS Number: 179324-69-7

Unique Ingredient Identifier: 69G8BD63PP

Background: Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.

Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.

Indication: Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.

Associated Conditions: Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)

Associated Therapies: -

Clinical Trials

A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: CC-220
Drug: Dexamethasone
Drug: Daratumumab
Drug: Carfilzomib
Drug: Bortezomib

First Posted Date: 2016-05-16

Last Posted Date: 2024-06-25

Lead Sponsor: Celgene

Target Recruit Count: 466

Registration Number: NCT02773030

Locations: 🇺🇸
Local Institution - 101, Atlanta, Georgia, United States
🇺🇸
Local Institution - 108, Hackensack, New Jersey, United States
🇺🇸
Local Institution - 115, Boston, Massachusetts, United States

and more 86 locations

Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma

Phase 4

Terminated

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: Melphalan
Drug: Prednisone

First Posted Date: 2016-05-16

Last Posted Date: 2020-01-18

Lead Sponsor: Basque Health Service

Target Recruit Count: 24

Registration Number: NCT02773550

Locations: 🇪🇸
Araba of University Hospital, Vitoria-Gasteiz, Araba, Spain

A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

Phase 3

Completed

Conditions: Relapsed/Refractory Multiple Myeloma

Interventions: Drug: Venetoclax
Drug: Bortezomib
Drug: Placebo for venetoclax
Drug: Dexamethasone

First Posted Date: 2016-04-29

Last Posted Date: 2023-08-22

Lead Sponsor: AbbVie

Target Recruit Count: 291

Registration Number: NCT02755597

Locations: 🇫🇷
CHU Limoges - Dupuytren 1 /ID# 149292, Limoges CEDEX 1, Franche-Comte, France
🇮🇹
Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona /ID# 148942, Ancona, Italy
🇦🇺
Box Hill Hospital /ID# 149112, Box Hill, Victoria, Australia

and more 94 locations

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Elotuzumab
Drug: Dexamethasone
Drug: Lenalidomide
Drug: Bortezomib
Drug: Pomalidomide
Drug: Nivolumab

First Posted Date: 2016-03-25

Last Posted Date: 2024-07-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 67

Registration Number: NCT02719613

Locations: 🇺🇸
Local Institution - 0009, Atlanta, Georgia, United States
🇺🇸
Local Institution - 0002, Boston, Massachusetts, United States
🇯🇵
Local Institution - 0048, Koto-ku, Tokyo, Japan

and more 38 locations

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Elotuzumab
Drug: Pomalidomide
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2016-03-24

Last Posted Date: 2024-04-16

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 52

Registration Number: NCT02718833

Locations: 🇺🇸
University of Rochester, Rochester, New York, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Newton-Wellesley Hospital, Newton, Massachusetts, United States

and more 3 locations

Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Granulocyte colony-stimulating factor (G-CSF)
Drug: Bortezomib
Drug: Mozobil

First Posted Date: 2016-03-09

Last Posted Date: 2021-06-18

Lead Sponsor: Siddhartha Ganguly

Target Recruit Count: 101

Registration Number: NCT02703779

Locations: 🇺🇸
The University of Kansas Medical Center, Westwood, Kansas, United States

Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma

Conditions: Multiple Myeloma in Relapse
Multiple Myeloma

First Posted Date: 2016-01-28

Last Posted Date: 2017-08-28

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT02666209

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

GO-203-2C + Bortezomib For Relapsed Or Refractory MM

Phase 1

Withdrawn

Conditions: Multiple Myeloma
Multiple Myeloma in Relapse
Refractory Multiple Myeloma

Interventions: Drug: GO-203-2C
Drug: Bortezomib

First Posted Date: 2016-01-18

Last Posted Date: 2017-07-05

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT02658396

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States